PREVIOUS QUESTION:

 

NEXT QUESTION:

 

Are there approved immunotherapy drugs for metastatic lung cancer?

ANSWER

In 2015 and 2016 the FDA approved three immunotherapy drugs to treat lung cancer that hasn’t responded well to chemotherapy or targeted therapies. These so-called “checkpoint inhibitors” are medicines that restart your immune system so it can recognize and fight cancer. This helps shrink or slow the growth of tumors.

SOURCES:

Cancer Support Community: “Frankly Speaking about Cancer: Treatments for Advanced and Metastatic Lung Cancer.”

National Comprehensive Cancer Network: “NCCN Guidelines for Patients: Lung Cancer/Non-Small Cell Lung Cancer.”

National Cancer Institute: “Biological Therapies for Cancer,” “Lung Cancer Precision Medicine Trials: Adapting to Progress,” “More Immunotherapy Options Approved for Lung Cancer,” “SEER Training Modules: “Combination Treatments,” “Targeted Cancer Therapies.”

Translational Lung Cancer Research : “Immunotherapy in Lung Cancer.”

Memorial Sloan Kettering Cancer Center: “Combination Immunotherapy Shows New Promise for Lung Cancer.”

Lungcancer.org: “Non-small Cell Lung Cancer Treatment.”

Cancer Immunology Research: “Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer.”

American Cancer Society: “Immunotherapy for non-small cell lung cancer,” “Targeted therapy drugs for non-small cell lung cancer.”

Lung Cancer Alliance: “Immunotherapy for Lung Cancer: A Guide for the Patient.”

FDA: “Atezolizumab (TECENTRIQ).”

Therapeutic Advances in Medical Oncology : “Checkpoint inhibitors in lung cancer: latest developments and clinical potential.”

Cancer Treatment Reviews : “The abscopal effect of local radiotherapy: using immunology to make a rare event clinically relevant.”

Cancer.net: “When the First Treatment Doesn’t Work.”

Reviewed by Arefa Cassoobhoy on February 5, 2019

SOURCES:

Cancer Support Community: “Frankly Speaking about Cancer: Treatments for Advanced and Metastatic Lung Cancer.”

National Comprehensive Cancer Network: “NCCN Guidelines for Patients: Lung Cancer/Non-Small Cell Lung Cancer.”

National Cancer Institute: “Biological Therapies for Cancer,” “Lung Cancer Precision Medicine Trials: Adapting to Progress,” “More Immunotherapy Options Approved for Lung Cancer,” “SEER Training Modules: “Combination Treatments,” “Targeted Cancer Therapies.”

Translational Lung Cancer Research : “Immunotherapy in Lung Cancer.”

Memorial Sloan Kettering Cancer Center: “Combination Immunotherapy Shows New Promise for Lung Cancer.”

Lungcancer.org: “Non-small Cell Lung Cancer Treatment.”

Cancer Immunology Research: “Immune Checkpoint Inhibitors: Making Immunotherapy a Reality for the Treatment of Lung Cancer.”

American Cancer Society: “Immunotherapy for non-small cell lung cancer,” “Targeted therapy drugs for non-small cell lung cancer.”

Lung Cancer Alliance: “Immunotherapy for Lung Cancer: A Guide for the Patient.”

FDA: “Atezolizumab (TECENTRIQ).”

Therapeutic Advances in Medical Oncology : “Checkpoint inhibitors in lung cancer: latest developments and clinical potential.”

Cancer Treatment Reviews : “The abscopal effect of local radiotherapy: using immunology to make a rare event clinically relevant.”

Cancer.net: “When the First Treatment Doesn’t Work.”

Reviewed by Arefa Cassoobhoy on February 5, 2019

NEXT QUESTION:

What are the types of immunotherapy drugs that are approved for metastatic lung cancer?

WAS THIS ANSWER HELPFUL

THIS TOOL DOES NOT PROVIDE MEDICAL ADVICE. It is intended for general informational purposes only and does not address individual circumstances. It is not a substitute for professional medical advice, diagnosis or treatment and should not be relied on to make decisions about your health. Never ignore professional medical advice in seeking treatment because of something you have read on the WebMD Site. If you think you may have a medical emergency, immediately call your doctor or dial 911.

    This tool does not provide medical advice. See additional information.

    Other Answers On: